Premium
Alinidine in angina
Author(s) -
Meinertz T,
Kasper W,
Meier R,
Wiegand U,
Bechtold H,
Förster I,
Pop T,
Jähnchen E
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.248
Subject(s) - medicine , angina , placebo , clinical pharmacology , heart rate , coronary artery disease , cardiology , anesthesia , double blind , pharmacology , myocardial infarction , blood pressure , alternative medicine , pathology
Alinidine—N‐allyl‐clonidine—reduces heart rate without blocking β adrenoreceptors. It may be used in patients with angina without inducing the adverse effects of β‐adrenergic blockers. We therefore evaluated alinidine efficacy in patients with angiographically proven coronary artery disease and stable angina during a 10‐wk placebo‐controlled randomized double‐blind trial. Alinidine (40 mg three times a day) reduced the number of anginal attacks and the average number of nitroglycerine capsules consumed. The double product was slightly lowered during rest but more pronounced during exercise. This effect was mainly due to decreased heart rate. The ischemie S‐T segment depression was diminished. Exercise tolerance was clearly improved in six, slightly improved in two, and unchanged in four subjects. Clinical Pharmacology and Therapeutics (1983) 34 , 770–776; doi: 10.1038/clpt.1983.248